117 related articles for article (PubMed ID: 22343167)
1. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years.
Fasano M; Lampertico P; Marzano A; Di Marco V; Niro GA; Brancaccio G; Marengo A; Scotto G; Brunetto MR; Gaeta GB; Rizzetto M; Angarano G; Santantonio T
J Hepatol; 2012 Jun; 56(6):1254-8. PubMed ID: 22343167
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
3. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.
Gramenzi A; Loggi E; Micco L; Cursaro C; Fiorino S; Galli S; Gitto S; Galli C; Furlini G; Bernardi M; Andreone P
J Viral Hepat; 2011 Oct; 18(10):e468-74. PubMed ID: 21914065
[TBL] [Abstract][Full Text] [Related]
4. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B.
Jin YJ; Shim JH; Chung YH; Kim JA; Choi JG; Park WH; Lee D; Kim SE; Lee YS; Kim SH; Yang SH
Digestion; 2011; 84 Suppl 1():35-42. PubMed ID: 22156484
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
7. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Yeh CT; Hsu CW; Chen YC; Liaw YF
J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
Kim JM; Choe BH; Chu MA; Cho SM
Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
[TBL] [Abstract][Full Text] [Related]
10. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
[TBL] [Abstract][Full Text] [Related]
11. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
[TBL] [Abstract][Full Text] [Related]
12. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
Yoon SK; Jang JW; Kim CW; Bae SH; Choi JY; Choi SW; Lee YS; Lee CD; Chung KW; Sun HS; Kim BS
Intervirology; 2005; 48(6):341-9. PubMed ID: 16024938
[TBL] [Abstract][Full Text] [Related]
14. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
[TBL] [Abstract][Full Text] [Related]
15. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
16. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
17. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
Jeong Id; Park NH; Kim BC; Park JH; Seo KW; Kim DH; Joo KR; Kim DH
Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):69-78. PubMed ID: 12824746
[TBL] [Abstract][Full Text] [Related]
19. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]